Grífols buys part of Novartis Diagnostics
The Catalan pharmaceutical company Grífols, based in Sant Cugat del Vallès, Barcelona, has bought part of the diagnostics unit of Swiss multinational Novartis for €1,240 million.
Grífols has acquired products and ‘in vitro’ technology applied to diagnoses in the fields of blood transfusion and immunology, along with patents, trademarks, licenses and commercial rights, as well as a production plant in Emeryville (California, USA) and sales offices in the US, Switzerland and Hong Kong.In 2012, the Catalan company had bought its main competitor in the United States, Telecaris, to become one of the main pharmaceutical companies in North America.
Grífols is the world’s third largest company in the production of blood-plasma derivatives. It distributes its products in more than 90 countries. Its subsidiaries operate directly in 24 countries including the US, Spain, Australia, China, Switzerland, Canada and Brazil.
In the first half of 2013, Grífols registered a profit of €182.2 million, an increase of 36.9% on the same period of 2012. With the acquisition, the Grífols Diagnostic Division will represent $1 billion, 20% of the Catalan group’s total revenues.
Source: ACN, 11/11/2013